148 related articles for article (PubMed ID: 28461099)
81. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
82. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
[TBL] [Abstract][Full Text] [Related]
83. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
[TBL] [Abstract][Full Text] [Related]
84. Sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA could effectively deliver siRNA to the liver.
Hattori Y; Arai S; Okamoto R; Hamada M; Kawano K; Yonemochi E
Int J Pharm; 2014 Dec; 476(1-2):289-98. PubMed ID: 25290812
[TBL] [Abstract][Full Text] [Related]
85. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
86. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice.
Kuramoto Y; Kawakami S; Zhou S; Fukuda K; Yamashita F; Hashida M
J Control Release; 2008 Mar; 126(3):274-80. PubMed ID: 18237815
[TBL] [Abstract][Full Text] [Related]
87. Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma.
Bansal D; Yadav K; Pandey V; Ganeshpurkar A; Agnihotri A; Dubey N
Drug Deliv; 2016; 23(1):140-6. PubMed ID: 24786484
[TBL] [Abstract][Full Text] [Related]
88. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
89. Development of a controlled-release drug delivery system by encapsulating oxaliplatin into SPIO/MWNT nanoparticles for effective colon cancer therapy and magnetic resonance imaging.
Lee PC; Lin CY; Peng CL; Shieh MJ
Biomater Sci; 2016 Nov; 4(12):1742-1753. PubMed ID: 27722406
[TBL] [Abstract][Full Text] [Related]
90. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
91. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Harashima H
Mol Ther; 2013 Jun; 21(6):1195-203. PubMed ID: 23568259
[TBL] [Abstract][Full Text] [Related]
92. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
93. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy.
Kang SH; Cho HJ; Shim G; Lee S; Kim SH; Choi HG; Kim CW; Oh YK
Pharm Res; 2011 Dec; 28(12):3069-78. PubMed ID: 21879387
[TBL] [Abstract][Full Text] [Related]
94. [Development of siRNA delivery strategy by active control of tumor microenvironment].
Ishida T; Kiwada H
Yakugaku Zasshi; 2013; 133(3):379-86. PubMed ID: 23449418
[TBL] [Abstract][Full Text] [Related]
95. Intravenous, non-viral RNAi gene therapy of brain cancer.
Pardridge WM
Expert Opin Biol Ther; 2004 Jul; 4(7):1103-13. PubMed ID: 15268677
[TBL] [Abstract][Full Text] [Related]
96. The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day.
Yang K; Zhao N; Zhao D; Chen D; Li Y
Drug Des Devel Ther; 2013; 7():511-7. PubMed ID: 23818762
[TBL] [Abstract][Full Text] [Related]
97. Enhancing solid tumor therapy with sequential delivery of dexamethasone and docetaxel engineered in a single carrier to overcome stromal resistance to drug delivery.
Zhang L; Su H; Liu Y; Pang N; Li J; Qi XR
J Control Release; 2019 Jan; 294():1-16. PubMed ID: 30527754
[TBL] [Abstract][Full Text] [Related]
98. NIR-light and GSH activated cytosolic p65-shRNA delivery for precise treatment of metastatic cancer.
Wang F; Huang Q; Wang Y; Shi L; Shen Y; Guo S
J Control Release; 2018 Oct; 288():126-135. PubMed ID: 30194946
[TBL] [Abstract][Full Text] [Related]
99. A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma.
Ando H; Saito-Tarashima N; Lila ASA; Kinjo N; Shimizu T; Ishima Y; Minakawa N; Ishida T
Molecules; 2020 Apr; 25(7):. PubMed ID: 32283709
[TBL] [Abstract][Full Text] [Related]
100. Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens.
Ando H; Abu Lila AS; Kawanishi M; Shimizu T; Okuhira K; Ishima Y; Ishida T
J Control Release; 2018 Jan; 270():114-119. PubMed ID: 29217175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
